&nbsp;

NewFundingModelDevelopment -RadiationTreatmentQuality-BasedProcedures.png

Sep 2019

Document

NewBackgroundRTP.png

Sep 2019

Document

newWindowIconPurple.png

Oct 2019

Statistical Reports

Key Findings

Document

NewOHCCO logo

Jan 2020

Neuroendocrine Tumours (NETs)

Regimen

NIVL+IPIL(MNT)

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - In Combination with Platinum Doublet Chemotherapy for First Line Metastatic or Recurrent Non-Small Cell Lung Cancer

New Drug Funding Program

Nivolumab plus Ipilimumab - In Combination with Platinum Doublet Chemotherapy for First Line Metastatic or Recurrent Non-Small Cell Lung Cancer

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Regimen Monograph

Nov 2024

Document

NursingPracticeContinuum.pdf

Jun 2021

Regimen

NIVL(MNT)

Cancer Type:

Skin,

Melanoma

Intent: Adjuvant

Drugs Used:

nivolumab (Unfunded)

Quick Link(s):

Regimen Monograph

Aug 2024

Regimen

NPAC(W)+PEMB

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Nab-Paclitaxel - Metastatic Breast Cancer

New Drug Funding Program

Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer

Drugs Used:

pembrolizumab,

nab-PACLitaxel

Quick Link(s):

Regimen Monograph

May 2024

Regimen

NIVL

Cancer Type:

Gastrointestinal,

Esophagus

Intent: Adjuvant

Funding:

New Drug Funding Program

Nivolumab - Adjuvant Treatment of Completely Resected Esophageal or Esophagogastric Junction Cancer

Drugs Used:

nivolumab